8D0Y

Crystal Structure of HIV-1 BG505 SOSIPv8 Trimer in Complex with CD4bs targeting antibody 21N13 and interface targeting antibody 35O22 at 4.7 Angstrom

8D0Y の概要

• エントリーDOI: 10.2210/pdb8d0y/pdb
• 関連するPDBエントリー: 5CEZ 8D01
• 分子名称: 35O22scFv Heavy Chain Variable, alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (13 entities in total)
• 機能のキーワード: hiv-1 cd4bs antibody; hiv-1 envelop protein;, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Macaca mulatta; 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 151906.51

構造登録者

Xian, Y.,Wilson, I.A. (登録日: 2022-05-26, 公開日: 2023-07-19, 最終更新日: 2026-01-14)

主引用文献

Caniels, T.G.,Medina-Ramirez, M.,Zhang, S.,Kratochvil, S.,Xian, Y.,Koo, J.H.,Derking, R.,Samsel, J.,van Schooten, J.,Pecetta, S.,Lamperti, E.,Yuan, M.,Carrasco, M.R.,Del Moral Sanchez, I.,Allen, J.D.,Bouhuijs, J.H.,Yasmeen, A.,Ketas, T.J.,Snitselaar, J.L.,Bijl, T.P.L.,Martin, I.C.,Torres, J.L.,Cupo, A.,Shirreff, L.,Rogers, K.,Mason, R.D.,Roederer, M.,Greene, K.M.,Gao, H.,Silva, C.M.,Baken, I.J.L.,Tian, M.,Alt, F.W.,Pulendran, B.,Seaman, M.S.,Crispin, M.,van Gils, M.J.,Montefiori, D.C.,McDermott, A.B.,Villinger, F.J.,Koup, R.A.,Moore, J.P.,Klasse, P.J.,Ozorowski, G.,Batista, F.D.,Wilson, I.A.,Ward, A.B.,Sanders, R.W.
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.
Sci Immunol, 9:eadk9550-eadk9550, 2024

PubMed Abstract: Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine development. Here, we describe how germline-targeting immunogen BG505 SOSIP germline trimer 1.1 (GT1.1), generated through structure-based design, engages a diverse range of VRC01-class bnAb precursors. A single immunization with GT1.1 expands CD4 binding site (CD4bs)-specific VRC01-class B cells in knock-in mice and drives VRC01-class maturation. In nonhuman primates (NHPs), GT1.1 primes CD4bs-specific neutralizing serum responses. Selected monoclonal antibodies (mAbs) isolated from GT1.1-immunized NHPs neutralize fully glycosylated BG505 virus. Two mAbs, 12C11 and 21N13, neutralize subsets of diverse heterologous neutralization-resistant viruses. High-resolution structures revealed that 21N13 targets the same conserved residues in the CD4bs as VRC01-class and CH235-class bnAbs despite its low sequence similarity (~40%), whereas mAb 12C11 binds predominantly through its heavy chain complementarity-determining region 3. These preclinical data underpin the ongoing evaluation of GT1.1 in a phase 1 clinical trial in healthy volunteers.

PubMed: 39213338
DOI: 10.1126/sciimmunol.adk9550

実験手法

X-RAY DIFFRACTION (4.7 Å)